Share This Author
Tigliane Diterpenoids as a New Type of Antiadipogenic Agents Inhibit GRα-Dexras1 Axis in Adipocytes.
A mechanistic study indicated that 1 and 1a could inhibit the glucocorticoid receptor α-Dexras1 axis in adipocyte, leading to the retardation of cell differentiation at the early stage, and may provide a new type of lipid-lowering agents for future antiobesity drug development.
Bouchardatine analogue alleviates non‐alcoholic hepatic fatty liver disease/non‐alcoholic steatohepatitis in high‐fat fed mice by inhibiting ATP synthase activity
The pharmacological effects of R17 in a model of NAFLD/NASH and its mode of action are examined, which shows benefits in the metabolic syndrome but not in the liver.
Discovery of a promising agent IQZ23 for the treatment of obesity and related metabolic disorders.
Bouchardatine suppresses rectal cancer in mice by disrupting its metabolic pathways via activating the SIRT1-PGC-1α-UCP2 axis.
Bouchardatine analogue alleviates NAFLD/NASH in high fat fed mice via blunting ATP synthase activity.
R17 has a therapeutic potential for NAFLD/NASH and its molecular mode of action involves the elimination of ER and oxidative stresses possibly via activating the LKB1-AMPK axis by blunting the activity of ATP synthase.
Total Flavonoids of Drynariae Rhizoma Improve Glucocorticoid-Induced Osteoporosis of Rats: UHPLC-MS-Based Qualitative Analysis, Network Pharmacology Strategy and Pharmacodynamic Validation
TFDR, which may play a crucial role between adipose metabolism and bone metabolism, may be a novel remedy for the prevention and clinical treatment of GIOP.